3-{5-[bis-(2-chloro-ethyl)-amino]-1-methyl-1H-benzoimidazol-2-yl}-propionic acid | 41515-12-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-{5-[bis-(2-chloro-ethyl)-amino]-1-methyl-1H-benzoimidazol-2-yl}-propionic acid
• 英文别名: 3-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]propanoic acid
• CAS: 41515-12-2
• 化学式: C₁₅H₁₉Cl₂N₃O₂
• 分子量: 344.241
• InChiKey: CAZLGRUIMIOHBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  58.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS, AND MEDICAL USE THEREOF IN CANCER THERAPY
  申请人：Helmut Schickaneder

  公开号：US20150152066A1

  公开（公告）日：2015-06-04

  The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.

  本发明涉及苯达莫司汀衍生物和相关化合物的公式（VII）、（VIII）和（IX），特别是在癌症治疗中的医学用途。
• [EN] BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS<br/>[FR] DÉRIVÉS DE BENDAMUSTINE ET SES COMPOSÉS
  申请人：SCHICKANEDER HELMUT

  公开号：WO2015091827A1

  公开（公告）日：2015-06-25

  The present invention relates to bendamustine derivatives and related compounds as well as their medical application.

  本发明涉及苯达莫司汀衍生物和相关化合物及其医学应用。
• Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy
  申请人：Schickaneder Helmut

  公开号：US10294208B2

  公开（公告）日：2019-05-21

  The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.

  本发明涉及苯达莫司汀衍生物和式 (VII)、(VIII) 和 (IX) 的相关化合物，以及它们在医学上的用途，特别是在癌症治疗中的用途。
• Hydroxamic Acid Derivatives
  申请人：Chen Yu

  公开号：US20110269706A1

  公开（公告）日：2011-11-03

  The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
• HYDROXAMIC ACID DERIVATIVES
  申请人：Purdue Pharmaceutical Products L.P.

  公开号：US20140066419A1

  公开（公告）日：2014-03-06

  The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein P, Z, and m are defined herein above.